39 results about "Glucose monitors" patented technology

This invention provides a precise control structure and applicator for the indwelling device in a continuous glucose monitoring (CGM) meter. By incorporating a clock structure consisting of an unlocking control track and a control block, different areas on the unlocking control track apply varying forces to the control block. These forces switch precisely upon completion of the puncture, allowing the clock structure to correlate with the puncture process. This enables the device to sense the puncture and promptly unlock the indwelling device after the procedure. This mechanical structure offers precise control and high integration, making it a glucose monitoring product that provides accurate control within a relatively small size.

Systems, computer programs, devices, and methods that enable coordination across multiple devices of the mobile ecosystem. In one embodiment, smart glasses detect when a user is about to eat food or take a drink and capture the consumable and portion. The data is recorded in a "morsel track" for health activity analysis. Low-fidelity captures provide preliminary recognition, while higher-fidelity captures are selectively invoked for definitive classification. Machine-learning logic generates predicted metabolic responses, such as real-time glucose trends, based on the recorded events. Predicted responses may dynamically adjust the operation of continuous glucose monitors, heart-rate sensors, or other biomedical devices. In some embodiments, the system triggers a pharmaceutical dispenser, such as an insulin pump, inhaler, or transdermal patch, to provide closed-loop therapeutic intervention in real time.

Glucose level measurements of a user are obtained over time, such as from a wearable glucose monitoring device being worn by the user. These glucose level measurements can be produced substantially continuously, such that the device may be configured to produce the glucose level measurements at regular or irregular intervals of time, responsive to establishing a communicative coupling with a different device, and so forth. These glucose level measurements are analyzed to detect deviations from past glucose measurements, such as glucose measurements received earlier in the day or glucose measurements received at corresponding times of one or more preceding days. Indications of detected deviations are provided to the user or communicated elsewhere, such as to a healthcare professional.

A glucose monitoring device is provided. The glucose monitoring device includes a housing having a first portion and a second portion, the second portion operable to be placed adjacent to a human body during operation of the glucose monitoring device. The glucose monitoring device further includes a circuit board positioned between the first portion and the second portion of the housing, the circuit board having a trace antenna. The glucose monitoring device further includes a conductive structure spaced apart from the circuit board.

The invention discloses a 3D nano microneedle electrode for improving glucose monitoring performance and a preparation method and application thereof, and relates to the technical field of biosensing. The 3D nanometer microneedle electrode for improving the glucose monitoring performance comprises a microneedle electrode base material and an electrode sensing material, the microneedle electrode base material is a stainless steel intradermal injection needle, the microneedle electrode base material is filled with a conductive filler, the conductive filler comprises carbon paste and silver paste, and the electrode sensing material comprises an inner layer structure and a surface layer structure. The inner-layer structure is a conductive nano-carrier, and the surface-layer structure is a compound enzyme layer. The invention also provides a preparation method of the 3D nano microneedle electrode for improving the glucose monitoring performance. The utilization rate and catalytic activity of Prussian blue are improved, electron transfer is accelerated, and the problems that a traditional glucose sensor is low in electron transfer efficiency, insufficient in stability and limited in detection range and accuracy are effectively solved.

Electrochemical impedance spectroscopy (EIS) is used in conjunction with continuous glucose monitors and continuous glucose monitoring (CGM) to enable in-vivo sensor calibration, total (sensor) failure analysis, and intelligent sensor diagnostics and failure detection. An equivalent circuit model is defined and each circuit element is used to characterize sensor behavior.

A compensation method for a continuous glucose monitor includes: acquiring a glucose value of a user continuously; determining a user type and a glucose trend type according to the glucose value, where the user type includes at least a first user type and a second user type; determining, based on the glucose value, whether a compensation start condition is satisfied;starting a compensation algorithm if the compensation start condition is satisfied; determining a compensation formula based on the glucose value and the glucose trend type; and obtaining, based on the glucose value and the compensation formula, a compensated glucose value until a compensation stop condition is satisfied.

The invention discloses an analysis model as well as a system and a method for applying the analysis model to multifunctional intelligent shoes for diabetes. The system comprises an intelligent shoe body, an intelligent terminal and a dynamic blood glucose monitor, the intelligent shoe body comprises a shoe body, a sole and an insole; the upper surface of the insole is divided into a plurality of sensing areas, and a pressure sensing module is arranged in each sensing area; a functional area is fixedly arranged on the shoe body, and a wireless module is installed in the functional area; the wireless module is electrically connected with each pressure sensing module through a connecting wire, and is wirelessly connected with the intelligent terminal and the dynamic blood glucose monitor. The intelligent terminal is provided with a blood glucose abnormal trend analysis model based on plantar pressure distribution, a long-short memory model is trained through subarea pressure distribution data according to different age groups, suspected and definite case data are analyzed from a test set, and therefore a distance model for distance definite diagnosis is constructed, and the function of early prevention of diseases is achieved.

The disclosed embodiments are directed to methods for dynamically adjusting the total daily insulin requirements of a user during pregnancy, based on the gestational week. An initial estimate of the adjusted total daily insulin requirement may be calculated as a multiple of the pre-pregnancy total daily insulin requirement, based on an average scale factor from a population of pregnant women suffering from Type I diabetes mellitus. An automatic drug delivery device may adjust the initial estimate of the total daily insulin requirement based on blood glucose level readings from a continuous glucose monitor during the course of the pregnancy.

Diabetes management systems may include a glucose monitoring device adapted to transmit glucose data and at least one accessory in communication with the glucose monitoring device and adapted to provide at least one alarm or alert based on the glucose data.

Diabetes prediction using glucose measurements and machine learning is described. In one or more implementations, an observation analysis platform includes a machine learning model trained using historical glucose measurements and historical outcome data for a population of users to predict a diabetes classification for an individual user. The historical glucose measurements for the population of users can be provided by glucose monitoring devices worn by users of the population of users, while the historical outcome data includes one or more diagnostic measurements obtained from a source independent of the glucose monitoring devices. After training is complete, the machine learning model predicts a diabetes classification for a user based on glucose measurements collected by a wearable glucose monitoring device over an observation period spanning multiple days. The predicted diabetes classification can then be output, such as by generating one or more notifications or user interfaces based on the classification.

Systems, computer programs, devices, and methods that enable coordination across multiple devices of the mobile ecosystem. In one embodiment, smart glasses detect when a user is about to eat food or take a drink and capture the consumable and portion. The data is recorded in a “morsel track” for health activity analysis. Low-fidelity captures provide preliminary recognition, while higher-fidelity captures are selectively invoked for definitive classification. Machine-learning logic generates predicted metabolic responses, such as real-time glucose trends, based on the recorded events. Predicted responses may dynamically adjust the operation of continuous glucose monitors, heart-rate sensors, or other biomedical devices. In some embodiments, the system triggers a pharmaceutical dispenser, such as an insulin pump, inhaler, or transdermal patch, to provide closed-loop therapeutic intervention in real time.

A system is provided comprising external device(s), tracking device(s) configured to generate blood glucose level data for tracked individual(s), and an alert device for management of alerts generated at the external device(s). The alert device comprises processor(s) and memory device(s). The memory device(s) comprise computer readable code that, when executed by the processor(s), causes the processor(s) to receive input data comprising blood glucose level data received from the tracking device(s), to determine an alert setting for an alert to be generated at an external device of the external device(s) based on the input data, and to generate a signal that causes the alert to be generated at the external device. The alert setting includes an identification of the external device where the alert is to be generated, an alert magnitude, and / or the alert type, with the alert type including an audible alert, a haptic alert, and / or a visual alert.

Embodiments include methods and systems for regulating a user's glucose levels. Systems comprise a processing unit in communication with a glucose monitor, an accelerometer, and a user interface. The glucose monitor generates glucose readings corresponding to the user's glucose levels and the accelerometer generates acceleration readings corresponding to the user's activity. The processing unit determines if the glucose readings indicate a glucose state and whether the acceleration readings indicate an activity state. If the glucose state and the activity state coincide, the processing unit sends a message to the user interface recommending a behavior that would influence the user's glucose level. Methods comprise determining, at a processing unit, if glucose readings indicate a glucose state, if acceleration readings indicate an activity state, whether the glucose state and activity state coincide and, if so, sending a message to a user interface recommending a behavior that would influence the user's glucose level.

A portable infusion pump can communicate with glucose monitor, such as a continuous glucose monitor (CGM), to receive continuous feedback relating to a user's blood glucose level during insulin or other medicament therapy and can automatically deliver insulin to a user when the CGM data indicates a need for additional insulin. Due to potential unreliability in the correlation of the CGM data to the user's actual blood glucose level, risk mitigation can be employed to limit the amount of extra insulin that can be delivered by the pump in response to the CGM data.

Systems, devices and methods are provided for incorporating a medication delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. The integrated management system may produce a plurality of reports that may include data related to analyte levels (e.g., glucose levels) and medication delivered (e.g., insulin delivered). The integrated system may also include a mode in which certain types of data are no longer shared and / or stored if the user is not signed into an account. The types of data shared and / or stored when the user is not signed into an account may differ from the types of data shared and / or stored when the user is signed into an account.

Glucose level measurements of a user are obtained over time, such as from a wearable glucose monitoring device being worn by the user. These glucose level measurements can be produced substantially continuously, such that the device may be configured to produce the glucose level measurements at regular or irregular intervals of time, responsive to establishing a communicative coupling with a different device, and so forth. These glucose level measurements are analyzed to detect deviations from past glucose measurements, such as glucose measurements received earlier in the day or glucose measurements received at corresponding times of one or more preceding days. Indications of detected deviations are provided to the user or communicated elsewhere, such as to a healthcare professional.

An assembly for securing a glucose monitoring device and related techniques are disclosed. The assembly may include a retainer member configured to fit loosely over the glucose monitoring device without attaching or connecting to it. To that end, the retainer member and a housing of the glucose monitoring device may include respective interfacing features configured to interface with one another. The assembly further may include an adhesive overpatch configured to adhere to the retainer member and the user's skin without adhering to the glucose monitoring device. In accordance with some embodiments, removal of the adhesive overpatch from the user's skin may effectuate simultaneous removal of the retainer member from the glucose monitoring device without compromising adhesion of the glucose monitoring device to the user's skin or disrupting placement of its implanted sensor.

The disclosed embodiments are directed to methods for dynamically adjusting the total daily insulin requirements of a user during pregnancy, based on the gestational week. An initial estimate of the adjusted total daily insulin requirement may be calculated as a multiple of the pre-pregnancy total daily insulin requirement, based on an average scale factor from a population of pregnant women suffering from Type I diabetes mellitus. An automatic drug delivery device may adjust the initial estimate of the total daily insulin requirement based on blood glucose level readings from a continuous glucose monitor during the course of the pregnancy.

A system for titrating a basal insulin dose that includes a glucose monitoring device configured to collect glucose data of a user, processors in communication with the glucose monitoring device, and a memory coupled to the processors. The processors are configured to determine an initial basal insulin dose, receive insulin data and glucose data during a titration period. The validity of each day is assessed, and a titration glucose level is determined for each valid day. The titration glucose level for each day is compared to glucose level thresholds, and a recommended adjustment to the basal insulin dose is determined based on the comparison.

The exemplary embodiments may provide a secure framework for devices in a drug delivery system to wirelessly communicate. The secure framework may use encrypted keys to carry credentials and to specify the rights of the devices presenting the credentials. The devices in the drug delivery system present the keys at the time that they wish to wirelessly communicate with other devices in the drug delivery system. The devices receiving such keys, decrypt the keys and verify if the credentials are valid. If the credentials are valid, a wireless communication session between devices may be established.

The invention provides a glucose monitoring system for glucose concentration before and after sleep and mobile equipment. The mobile equipment comprises a processing module and a display module, the processing module is used for determining the fluctuation type of a glucose concentration curve before sleep and after sleep on the basis of glucose data including the time-varying glucose concentration of the to-be-detected object before sleep and after sleep, and the glucose data is obtained by acquiring the glucose concentration in interstitial fluid by the sensing module at a preset frequency; the fluctuation type reflects the change trend of the glucose concentration between before sleep and after sleep, and guidance information or suggestions related to sleep behaviors are generated according to the fluctuation type; and the display module is used for displaying at least one of the guidance information, the glucose concentration curve and the fluctuation type. Therefore, the time for seeking suggestions of doctors can be reduced.

The present disclosure relates to a system and method to predict the post- prandial glucose response in the individuals type 2 diabetes mellitus (T2DM) in India by taking sample of patients with T2DM from various locations across India and fitting them with continuous glucose monitors (CGM) and calculating the postprandial glucose response based on the different meal intakes by the patients. The present disclosure further relates to the utilization of k-means clustering models to classify food types based on nutritional information and classification of patients. The present disclosure also relates to utilizing XGBoost to predict postprandial blood glucose responses based on patient phenotypes and food categories and providing personalized recommendations taking into account meal type, preferences, and regional influences which would allow patients with T2DM to eat and drink foods to maintain their blood sugar within prescribed limits and prevent disease progression.

Systems and methods are described for determining a reference blood glucose (RefBG) metric and for determining a medicament dose or dose adjustment for a subject based at least in part the reference blood glucose metric. The RefBG metric is based on continuous and / or intermittent glucose monitoring samples and can be derived from a specified time window of the samples. One or more additional metrics of a therapeutic performance of the subject may be modeled and used to establish a target value for the RefBG metric, which may be compared to historical RefBG values to determine dose values to be avoided in future updates of medicament doses.

The invention relates to the technical field of medical apparatuses and instruments, in particular to a dynamic glucose monitoring equipment removing instrument which comprises a main body part provided with a containing cavity capable of containing a sensor; the rotating sleeve is arranged on the main body piece in a sleeving mode and can axially rotate relative to the main body piece, a mounting cavity is formed between the rotating sleeve and the main body piece and communicates with the containing cavity, and the rotating sleeve is further provided with a plurality of abutting protrusions located in the mounting cavity; the heating device is arranged in the containing cavity, and the heating device can heat the interior of the containing cavity; the plurality of abutting pieces are arranged in the mounting cavity, each abutting piece is provided with an abutting wall, and the plurality of abutting protrusions can be in sliding contact with one abutting wall respectively; when the rotating sleeve rotates, the abutting protrusions make sliding contact with the abutting walls and push all the abutting pieces to rotate relative to the main body piece, so that all the abutting pieces partially extend into the containing cavity from the communicating position of the mounting cavity and the containing cavity.

The present application provides a kind of contact lens type tear glucose sensing monitoring system, comprising: substrate, the substrate is made of flexible transparent material;Bionic microfluid channel sample collection module, the bionic microfluid channel sample collection module is used to collect tear fluid;Tear glucose monitoring sensor, the tear glucose monitoring sensor is used to detect the glucose content in tear fluid, the tear glucose monitoring sensor is connected with the bionic microfluid channel sample collection module;Wireless signal transmission module, the wireless signal transmission module is connected with the tear glucose monitoring sensor;Contact lens external circuit module, the contact lens external circuit module is used to receive the detection result signal transmitted by the wireless signal transmission module;The bionic microfluid channel sample collection module, the tear glucose monitoring sensor and the wireless signal transmission module are all arranged on the substrate. Can improve the security, comfort and portability of eye physiological information monitoring.

1. The name of the design product: dynamic blood glucose meter sensor. 2. The use of the design product: the design product is used for applying on the skin surface of the user to collect the blood glucose information in the body. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1.

Introduced here are diabetes management platforms able to examine glucose measurements associated with a subject to discover patterns indicative of similar behaviors / circumstances. More specifically, a diabetes management platform can acquire multiple data series generated by a glucose monitoring device that monitors the blood glucose level of an individual over multiple time intervals. The diabetes management platform can then apply a similarity algorithm to produce a distance measure (also referred to as a “similarity measure”) for each data series. For example, the diabetes management platform may, for each data series, perform dynamic time warping to produce a distance measure with respect to each of the other data series. The diabetes management platform can identify patterns indicative of similar behaviors / circumstances based on these distance measures.